ERNA · XBRL financial data
Ernexa Therapeutics financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ERNA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 5,800 | — | 0 | 68 | 582 | — |
| Revenue from contracts with customers | 5,800 | — | — | — | — | — |
| Cost of revenue | — | — | 0 | 236 | 96 | — |
| Gross profit | — | — | 0 | (168) | 486 | — |
| Research and development | 2 | — | — | — | — | — |
| Selling, general and administrative | 8,091 | — | — | — | — | — |
| General and administrative | 3,297 | 14,724 | 16,835 | 14,587 | 13,132 | 5,163 |
| Total operating expenses | 12,109 | 113,732 | 33,217 | 20,967 | 16,160 | 9,319 |
| Operating income (loss) | (6,309) | (113,732) | (33,217) | (21,135) | (15,674) | (9,319) |
| Interest expense | 118 | — | 30 | 614 | 6,500 | (100) |
| Other income (expense) | 1,888 | 899 | (1,171) | (334) | 70 | 215 |
| Income tax expense (benefit) | (6) | 64 | 45 | (3) | 30 | (45) |
| Net income (loss) | (4,415) | (122,545) | (24,579) | (21,668) | (44,539) | (14,084) |
| Earnings per share, basic‡ USD per share | (8.20) | (56.60) | (8.06) | (4.08) | (3.26) | (2.24) |
| Earnings per share, diluted‡ USD per share | (8.20) | (56.60) | (8.06) | (4.08) | (3.26) | (2.24) |
| Weighted average shares, basic‡ thousands of shares | 879 | 2,165 | 3,051 | 5,314 | 13,647 | 6,307 |
| Weighted average shares, diluted‡ thousands of shares | 879 | 2,165 | 3,051 | 5,314 | 13,647 | 6,307 |
- ‡ Per-share figures and share counts are adjusted for the 2-for-1 stock split (March 2021); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2022); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal years (ERNA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 777 | 16,985 | 11,446 | 7,575 | 1,729 | 1,884 |
| Accounts receivable | 116 | 684 | — | — | — | — |
| Prepaid and other current assets | 176 | 1,097 | 1,284 | 1,599 | 186 | 404 |
| Total current assets | 1,724 | 18,766 | 13,681 | 9,599 | 2,352 | 3,133 |
| Property and equipment, net | 502 | 670 | 236 | 493 | 85 | 94 |
| Right-of-use asset | 36 | 2,567 | 1,030 | 32,781 | 670 | 453 |
| Goodwill | 2,044 | 2,044 | 2,044 | 2,044 | 2,044 | 2,044 |
| Total assets | 3,745 | 31,525 | 22,279 | 49,132 | 5,269 | 5,834 |
| Accounts payable | 270 | 1,755 | 1,620 | 1,067 | 1,721 | 1,125 |
| Accrued liabilities | 238 | 1,249 | 3,626 | 1,893 | 1,007 | 898 |
| Current portion of long-term debt | 1,500 | — | — | — | — | — |
| Total current liabilities | 2,360 | 3,677 | 7,654 | 6,573 | 2,938 | 3,113 |
| Long-term debt | 532 | — | — | — | — | — |
| Lease liability, non-current | 1,905 | 2,297 | 887 | 32,854 | 477 | 277 |
| Total liabilities | 2,894 | 6,022 | 10,172 | 46,899 | 3,568 | 3,433 |
| Accumulated deficit | (135,888) | (140,702) | (165,297) | (186,981) | (231,536) | (245,636) |
| Total stockholders' equity | 851 | 25,503 | 12,107 | 2,233 | 1,701 | 2,401 |
| Total liabilities and equity | 3,745 | 31,525 | 22,279 | 49,132 | 5,269 | 5,834 |
| Common shares outstanding (cover page)‡ thousands of shares | 298 | 2,873 | 5,127 | 5,410 | 52,245 | 29,154 |
- ‡ Per-share figures and share counts are adjusted for the 2-for-1 stock split (March 2021); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2022); filings made before it reported them unadjusted.
Cash flows
CSVFiscal years (ERNA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (4,415) | (122,545) | (24,579) | (21,668) | (44,539) | (14,084) |
| Stock-based compensation | 199 | 5,235 | 2,935 | 1,242 | 1,520 | 1,496 |
| Depreciation and amortization | 98 | 117 | 161 | 84 | 139 | 65 |
| Net cash from operating activities | (3,894) | (23,488) | (20,976) | (20,408) | (15,836) | (7,017) |
| Purchases of property and equipment | 39 | 154 | 297 | 19 | 369 | 37 |
| Net cash from investing activities | 960 | (22,742) | (47) | (19) | (365) | (37) |
| Proceeds from issuing common stock | 0 | 52,025 | 19,706 | 0 | 1,137 | 4,929 |
| Proceeds from issuing equity | — | — | — | — | — | 7,201 |
| Proceeds from long-term debt | 3,125 | — | — | — | — | — |
| Repayments of long-term debt | 2,750 | — | — | — | — | — |
| Net cash from financing activities | 291 | 61,585 | 19,579 | 16,556 | 6,260 | 7,209 |
| Net change in cash | (2,632) | — | — | — | — | — |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Ernexa Therapeutics | 5,028 | not reported | (4,152)* | 1.6M | 1.2 quarters | 10-QJun 30, 2026 |
| Marker Therapeutics | 11,331 | not reported | (3,716)* | 16.7M | 3.0 quarters | 10-QJun 30, 2026 |
| Charlie's Holdings | 527 | not reported | (383)* | 280.6M | 1.4 quarters | 10-QJun 30, 2026 |
| Cognition Therapeutics | 34,012 | not reported | (3,053)* | 95.1M | 11.1 quarters | 10-QJun 30, 2026 |
| IGC Pharma | 331 | 265 | (1,350)* | 103.4M | 0.3 quarters | 10-QJun 30, 2026 |
| Lipocine | 4,979 | 190 | (3,028)* | 8.2M | 7.7 quarters | 10-QJun 30, 2026 |
| Relmada Therapeutics | 11,334 | not reported | (9,606)* | 106.7M | 22.7 quarters | 10-QJun 30, 2026 |
| CEL-SCI | 6,527 | not reported | (4,031)* | 17.6M | 1.6 quarters | 10-QJun 30, 2026 |
| CalciMedica | 18,617 | not reported | (4,620)* | 34.1M | 4.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.